Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics, and antitumor activity of dacetuzumab in patients with refractory or recurrent B-cell non-Hodgkin's lymphoma (NHL). In this open-label, dose-escalation phase I study, dacetuzumab was administered to six cohorts of adult pat...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical oncology Vol. 27; no. 26; p. 4371
Main Authors: Advani, Ranjana, Forero-Torres, Andres, Furman, Richard R, Rosenblatt, Joseph D, Younes, Anas, Ren, Hong, Harrop, Kate, Whiting, Nancy, Drachman, Jonathan G
Format: Journal Article
Language:English
Published: United States 10.09.2009
Subjects:
Adult
Aged
Aged, 80 and over
Anemia - chemically induced
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - pharmacokinetics
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
CD40 Antigens - immunology
Cohort Studies
Cytokines - blood
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Fatigue - chemically induced
Female
Fever - chemically induced
Headache - chemically induced
Humans
Lymphoma, B-Cell - drug therapy
Lymphoma, B-Cell - metabolism
Lymphoma, Non-Hodgkin - drug therapy
Lymphoma, Non-Hodgkin - metabolism
Male
Middle Aged
Recurrence
Treatment Outcome
Young Adult
ISSN:1527-7755, 1527-7755
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics, and antitumor activity of dacetuzumab in patients with refractory or recurrent B-cell non-Hodgkin's lymphoma (NHL). In this open-label, dose-escalation phase I study, dacetuzumab was administered to six cohorts of adult patients. In the first cohort, patients received 2 mg/kg weekly for 4 weeks; in all other cohorts, an intrapatient dose-escalation schedule was used with increasing doses up to a maximum of 8 mg/kg. Patients with clinical benefit after one cycle of dacetuzumab were eligible for a second cycle. In the 50 patients who received dacetuzumab, no dose dependence of adverse events (AEs) was observed. The most common AEs in >or= 20% of patients were fatigue, pyrexia, and headache; most were grade 1 or 2. Noninfectious inflammatory eye disorders occurred in 12% of patients. AEs grade >or= 3 occurred in 30% of patients and included disease progression, anemia, pleural effusion, and thrombocytopenia. Most laboratory abnormalities were grade 1 or 2; transient elevated hepatic aminotransferases occurred in 52% of patients. Two patients experienced dose-limiting toxicity: grade 3 conjunctivitis and transient vision loss in cohort (1), and grade 3 ALT elevation in cohort IV. The MTD of dacetuzumab was not established at the dose levels tested. Six objective responses were reported (one complete response, five partial responses). Tumor size decreased in approximately one third of patients. Dacetuzumab monotherapy was well tolerated in patients with NHL in doses up to 8 mg/kg/wk. Preliminary response data are encouraging and support additional studies of dacetuzumab in this patient population.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1527-7755
1527-7755
DOI:10.1200/JCO.2008.21.3017